Meeting
2021 ASCO Annual Meeting
Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab (P+T) in the APHINITY trial.
Authors
Evandro de Azambuja
Institut Jules Bordet and Université Libre de Bruxelles (U.L.B), Brussels, Belgium
Evandro de Azambuja , Daniel Eiger , Marion Jennifer Procter , Noam Falbel Ponde , Sebastien Guillaume , Damien Parlier , Matteo Lambertini , Antoine Desmet , Carmela Aves Caballero , Christian Aguila , Guy Heinrich Maria Jerusalem , Janice Maria Walshe , Elizabeth S. Frank , Jose Bines , Sibylle Loibl , Martine J. Piccart-Gebhart , Michael S. Ewer , Susan Faye Dent , Chris Plummer , Thomas M Suter
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT01358877
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 510)
DOI
10.1200/JCO.2021.39.15_suppl.510
Abstract #
510
Abstract Disclosures
Similar Posters
First Author: Nicholas Patrick McAndrew
Poster
2020 ASCO Virtual Scientific Program
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function.
First Author: Katia Khoury
Poster
2017 ASCO Annual Meeting
A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).
First Author: Ines Maria Vaz Duarte Luis
Poster
2017 ASCO Annual Meeting
Eribulin in combination with pertuzumab plus trastuzumab for HER2-positive advanced or recurrent breast cancer (JBCRG-M03).
First Author: Kazutaka Narui